CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
comprehensive clinical update on zugocaptagene geleucel (zugo-cel), formerly known as CTX112. This investigational allogeneic (off-the-shelf) CAR T therapy targets CD19 and is currently being evaluated for both autoimmune diseases and hematologic malignancies. By using CRISPR Cas9 for targeted gene modification, zugo-cel is designed to enhance T-cell potency and evade immune detection without the need for HLA matching. Preliminary data from an ongoing Phase 1 basket trial involving systemic lupus erythematosus/SLE, systemic sclerosis, and inflammatory myositis show that zugo-cel is well-tolerated and highly effective. As of the December 17 data cut-off, four patients (two with SLE and two with immune-mediated necrotizing myopathy) received a dose of 100 million cells. All four demonstrated rapid and deep peripheral B-cell depletion within 48 hours, which was sustained for at least 28 days. Notably, the first SLE patient treated has achieved drug-free DORIS clinical remission through
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock [Seeking Alpha]Seeking Alpha
- Cathie Wood drops $1.3 million on healthcare stock [Yahoo! Finance]Yahoo! Finance
- Is CRISPR Therapeutics Stock Yesterday's News? [Yahoo! Finance]Yahoo! Finance
- How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors [Yahoo! Finance]Yahoo! Finance
- 3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 12/23/25 - Form 4
- 12/22/25 - Form 4
- 12/22/25 - Form 144
- CRSP's page on the SEC website